Insider · CIK 0001969857
Jean-Manasse Theagene
Files at MAIA (MAIA Biotechnology, Inc.). First filing -, latest -.
In brief
Jean-Manasse Theagene files SEC Form 4 as director at MAIA (MAIA Biotechnology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jean-Manasse Theagene has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +32,012 | $0.00 | $0 | 32,012 | 11 d ago |
| Jun 30, 2026 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +26,355 | $0.00 | $0 | 26,355 | Jul 2, 2026 |
| Mar 31, 2026 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +27,258 | $0.00 | $0 | 27,258 | Apr 2, 2026 |
| Dec 31, 2025 | MAIA MAIA Biotechnology, Inc. | AGrant or award Optionsderivative | +24,060 | $0.00 | $0 | 24,060 | Jan 5, 2026 |
| Oct 2, 2025 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +20,459 | $0.00 | $0 | 20,459 | Oct 6, 2025 |
| Jun 30, 2025 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +20,380 | $0.00 | $0 | 20,380 | Jul 2, 2025 |
| Apr 4, 2025 | MAIA MAIA Biotechnology, Inc. | AGrant or award Stock Optionsderivative | +20,291 | $0.00 | $0 | 20,291 | Apr 8, 2025 |
Questions about Jean-Manasse Theagene
Answered from the filings on this page, as of the latest one.
Is Jean-Manasse Theagene buying or selling?
Jean-Manasse Theagene has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jean-Manasse Theagene's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jean-Manasse Theagene has 0.
Where does Jean-Manasse Theagene file Form 4?
Jean-Manasse Theagene has filed Form 4 at MAIA (MAIA Biotechnology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.